This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Cobra Biologics will apply its cost-effective platform process to deliver a programme of host strain generation, GMP cell banking, plasmid DNA production and clinical trials supply.
Vaccibody’s technology exploits the interplay between tissue, antigen presenting cells (APC), T-cells and B-cells to develop targeted vaccines designed to induce stronger and longer lasting immune responses than traditional vaccines. The platform technology allows for the tailored development of not only enhanced prophylactic vaccines but also therapeutic vaccines against chronic infections and cancers.
Peter Coleman CEO of Cobra Biologics said “Cobra has been manufacturing plasmid therapeutics and DNA vaccines for more than 14 years and I am delighted that we are able to announce the partnership with Vaccibody. Our DNA platform process is based on Cobra’s pioneering heritage in gene therapy manufacturing and technology development that we have successfully used for over 30 customers”.
Ole Henrik Brekke, CEO of Vaccibody said “With the significantly effective preclinical results VB 10.16 has shown, we are delighted now to take the next step towards clinical trials with Cobra Biologics as our manufacturing partner.”
For more information about Cobra Biologics, please contact Peter Coleman, CEO, on +44 (0)1782 714181 or email peter.coleman@cobrabio.com
For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0)207 861 3019 or email: t.jervis@defacto.com.
